+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Gene Therapy Market - Global Forecast 2026-2032- Product Image
Gene Therapy Market - Global Forecast 2026-2032- Product Image
New

Gene Therapy Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 199 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 4858031
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The gene therapy market is in a transformative phase as cross-disciplinary innovation, operational advancement, and rising regulatory complexity converge. Senior decision-makers must orchestrate internal capabilities and external partnerships to unlock scalable value and stay competitive.

Market Snapshot: Gene Therapy Market Size and Growth

The gene therapy market is experiencing robust expansion, with revenues projected to grow from USD 12.91 billion in 2025 to USD 16.35 billion in 2026. Continued momentum is expected, driven by a compound annual growth rate (CAGR) of 28.80%, reaching USD 75.92 billion by 2032. This trajectory underscores the impact of scientific innovation, increased commercial investment, and global collaboration. For senior leaders, this growth signals an evolving competitive landscape that demands foresight in partnership management, talent acquisition, and manufacturing scale-up as the market matures.

Scope & Segmentation

  • Vector Types: Viral vectors (adeno-associated virus, lentivirus, adenovirus, herpes simplex virus, retrovirus) and non-viral agents (lipid nanoparticles, plasmid DNA) each influence safety, delivery, and therapeutic applications.
  • Treatment Modalities: Approaches include somatic cell therapy, gene augmentation, gene suppression, and germline interventions, all informed by evolving regulatory frameworks and bioethics.
  • Genome Targets: Both DNA and RNA are targeted, extending the reach into diverse genetic pathologies and broad application domains beyond rare diseases.
  • Delivery Methods: Ex vivo (external cell manipulation) and in vivo (direct body administration) strategies introduce unique operational and scale-up requirements.
  • Administration Routes: Modalities such as intramuscular, intravenous, and intraocular enable tailored protocols for optimized patient outcomes.
  • Patient Demographics: Solutions address both adult and pediatric segments, shaping clinical trial design, dosing strategies, and market access planning.
  • Therapeutic Areas: Indications span monogenic disorders, cancers, cardiovascular, infectious, and other specialized disease states.
  • End-User Segments: Stakeholders include pharmaceutical and biotech firms, hospitals, clinics, research organizations, and academic institutes, each with distinct commercialization pathways.
  • Geographic Coverage: Key markets comprise the Americas, Europe, Middle East & Africa, and Asia-Pacific, with regional variation informing regulatory pace and market entry strategies.
  • Technology Focus: Advances in vector engineering, modular manufacturing, digital and computational platforms are streamlining processes, ensuring product consistency, and enabling scalability.

Key Takeaways: Strategic Gene Therapy Insights

  • Rapid commercialization is being fueled by greater scientific maturity and advances in manufacturing, bridging former translational gaps.
  • Collaborative models integrating biotech firms, academic centers, and contract manufacturers have become essential for operational efficiency and early-stage clinical development.
  • Regulatory agencies are streamlining approval processes and emphasizing post-market safety, requiring heightened compliance and continuous patient monitoring.
  • Payer engagement and evolving health technology assessment standards are shaping new reimbursement models, including real-world data requirements influencing commercialization.
  • Targeted segmentation by vector, disease area, and technology informs stakeholder clinical, operational, and market access priorities for sustained advantage.
  • End-user diversity underscores the need for strong alignment between research, development, and commercial teams to navigate complex market pathways.

Tariff Impact: Navigating Supply Chain Disruption

The imposition of new U.S. tariffs in 2025 has introduced additional supply chain complexity within the gene therapy sector. Organizations are adapting by expanding supplier networks, initiating multi-year sourcing contracts, and investing in local manufacturing. These strategies are designed to secure program continuity, address global trade policy shifts, and manage variable costs, ultimately supporting timely and compliant therapy development.

Methodology & Data Sources

This analysis integrates structured interviews with experts in clinical, regulatory, and manufacturing domains. A detailed examination of peer-reviewed publications, regulatory filings, clinical trial registries, and public disclosures supports scenario analysis and expert validation, ensuring all projections and insights are actionable and precise.

Why This Report Matters

  • Provides senior leaders with a framework to assess technology impact and regulatory change on product pipelines and investment plans.
  • Offers actionable segmentation to refine partnership targeting and enhance competitive positioning in emerging and established regions.
  • Enables supply chain resilience and accelerates translation through multidisciplinary strategic guidance, directly supporting long-term business and clinical objectives.

Conclusion

Synchronized action across development, operations, and commercial strategy is essential for effective participation in the gene therapy arena. Ongoing adaptability and cross-functional alignment will maximize patient benefit and secure sustained organizational progress.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Gene Therapy Market, by Vector Type
8.1. Non-Viral Vectors
8.1.1. Lipofection
8.1.2. Plasmid DNA
8.2. Viral Vectors
8.2.1. Adeno-Associated Virus (AAV) Vectors
8.2.2. Adenovirus Vectors
8.2.3. Herpes Simplex Virus (HSV) Vectors
8.2.4. Retrovirus Vectors
9. Gene Therapy Market, by Treatment Modality
9.1. Germline Therapy
9.2. Somatic Cell Therapy
9.2.1. Gene Augmentation Therapy
9.2.2. Gene Suppression Therapy
10. Gene Therapy Market, by Target Genome
10.1. DNA Modification
10.2. RNA Modification
11. Gene Therapy Market, by Delivery Mode
11.1. Ex Vivo
11.2. In Vivo
12. Gene Therapy Market, by Route of Administration
12.1. Intramuscular
12.2. Intraocular
12.3. Intravenous
13. Gene Therapy Market, by Patient Type
13.1. Adult Patients
13.2. Pediatric Patients
14. Gene Therapy Market, by Therapeutic Area
14.1. Cardiovascular Diseases
14.1.1. Coronary Artery Disease
14.1.2. Heart Failure
14.2. Infectious Diseases
14.2.1. Hepatitis B
14.2.2. HIV
14.3. Monogenic Disorders
14.3.1. Cystic Fibrosis
14.3.2. Hemophilia
14.3.3. Sickle Cell Anemia
14.4. Oncological Disorders
14.4.1. Hematological Malignancies
14.4.2. Solid Tumors
15. Gene Therapy Market, by End-User
15.1. Contract Research Organizations
15.2. Hospitals & Clinics
15.3. Pharmaceutical & Biotech Companies
15.4. Research Institutes
16. Gene Therapy Market, by Region
16.1. Americas
16.1.1. North America
16.1.2. Latin America
16.2. Europe, Middle East & Africa
16.2.1. Europe
16.2.2. Middle East
16.2.3. Africa
16.3. Asia-Pacific
17. Gene Therapy Market, by Group
17.1. ASEAN
17.2. GCC
17.3. European Union
17.4. BRICS
17.5. G7
17.6. NATO
18. Gene Therapy Market, by Country
18.1. United States
18.2. Canada
18.3. Mexico
18.4. Brazil
18.5. United Kingdom
18.6. Germany
18.7. France
18.8. Russia
18.9. Italy
18.10. Spain
18.11. China
18.12. India
18.13. Japan
18.14. Australia
18.15. South Korea
19. United States Gene Therapy Market
20. China Gene Therapy Market
21. Competitive Landscape
21.1. Market Concentration Analysis, 2025
21.1.1. Concentration Ratio (CR)
21.1.2. Herfindahl Hirschman Index (HHI)
21.2. Recent Developments & Impact Analysis, 2025
21.3. Product Portfolio Analysis, 2025
21.4. Benchmarking Analysis, 2025
21.5. Abeona Therapeutics Inc.
21.6. Adaptimmune Therapeutics PLC
21.7. Adverum Biotechnologies, Inc.
21.8. AGC Biologics
21.9. Alnylam Pharmaceuticals, Inc.
21.10. American Gene Technologies Inc.
21.11. Amgen Inc.
21.12. AnGes, Inc.
21.13. Astellas Pharma Inc.
21.14. Biogen Inc.
21.15. bluebird bio, Inc.
21.16. Cellectis S.A.
21.17. CRISPR Therapeutics AG
21.18. Danaher Corporation
21.19. Editas Medicine, Inc.
21.20. F. Hoffmann-La Roche Ltd.
21.21. Gilead Sciences, Inc.
21.22. Intellia Therapeutics
21.23. Ionis Pharmaceuticals, Inc.
21.24. Johnson & Johnson
21.25. Merck KGaA
21.26. Mustang Bio, Inc.
21.27. Novartis AG
21.28. Orchard Therapeutics PLC
21.29. Poseida Therapeutics, Inc.
21.30. Sangamo Therapeutics, Inc.
21.31. Sarepta Therapeutics, Inc.
21.32. Sibiono GeneTech Co. Ltd.
21.33. Syncona Limited
21.34. ViGeneron GmbH
21.35. Voyager Therapeutics Inc.
List of Figures
FIGURE 1. GLOBAL GENE THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL GENE THERAPY MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL GENE THERAPY MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL GENE THERAPY MARKET SIZE, BY TREATMENT MODALITY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL GENE THERAPY MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL GENE THERAPY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 13. GLOBAL GENE THERAPY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL GENE THERAPY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 15. UNITED STATES GENE THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 16. CHINA GENE THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL GENE THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL GENE THERAPY MARKET SIZE, BY LIPOFECTION, BY REGION, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL GENE THERAPY MARKET SIZE, BY LIPOFECTION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL GENE THERAPY MARKET SIZE, BY LIPOFECTION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL GENE THERAPY MARKET SIZE, BY PLASMID DNA, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL GENE THERAPY MARKET SIZE, BY PLASMID DNA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL GENE THERAPY MARKET SIZE, BY PLASMID DNA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL GENE THERAPY MARKET SIZE, BY ADENO-ASSOCIATED VIRUS (AAV) VECTORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL GENE THERAPY MARKET SIZE, BY ADENO-ASSOCIATED VIRUS (AAV) VECTORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL GENE THERAPY MARKET SIZE, BY ADENO-ASSOCIATED VIRUS (AAV) VECTORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL GENE THERAPY MARKET SIZE, BY ADENOVIRUS VECTORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL GENE THERAPY MARKET SIZE, BY ADENOVIRUS VECTORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL GENE THERAPY MARKET SIZE, BY ADENOVIRUS VECTORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL GENE THERAPY MARKET SIZE, BY HERPES SIMPLEX VIRUS (HSV) VECTORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL GENE THERAPY MARKET SIZE, BY HERPES SIMPLEX VIRUS (HSV) VECTORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL GENE THERAPY MARKET SIZE, BY HERPES SIMPLEX VIRUS (HSV) VECTORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL GENE THERAPY MARKET SIZE, BY RETROVIRUS VECTORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL GENE THERAPY MARKET SIZE, BY RETROVIRUS VECTORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL GENE THERAPY MARKET SIZE, BY RETROVIRUS VECTORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL GENE THERAPY MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL GENE THERAPY MARKET SIZE, BY GERMLINE THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL GENE THERAPY MARKET SIZE, BY GERMLINE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL GENE THERAPY MARKET SIZE, BY GERMLINE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL GENE THERAPY MARKET SIZE, BY SOMATIC CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL GENE THERAPY MARKET SIZE, BY SOMATIC CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL GENE THERAPY MARKET SIZE, BY SOMATIC CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL GENE THERAPY MARKET SIZE, BY SOMATIC CELL THERAPY, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL GENE THERAPY MARKET SIZE, BY GENE AUGMENTATION THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL GENE THERAPY MARKET SIZE, BY GENE AUGMENTATION THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL GENE THERAPY MARKET SIZE, BY GENE AUGMENTATION THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL GENE THERAPY MARKET SIZE, BY GENE SUPPRESSION THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL GENE THERAPY MARKET SIZE, BY GENE SUPPRESSION THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL GENE THERAPY MARKET SIZE, BY GENE SUPPRESSION THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL GENE THERAPY MARKET SIZE, BY DNA MODIFICATION, BY REGION, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL GENE THERAPY MARKET SIZE, BY DNA MODIFICATION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL GENE THERAPY MARKET SIZE, BY DNA MODIFICATION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL GENE THERAPY MARKET SIZE, BY RNA MODIFICATION, BY REGION, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL GENE THERAPY MARKET SIZE, BY RNA MODIFICATION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL GENE THERAPY MARKET SIZE, BY RNA MODIFICATION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL GENE THERAPY MARKET SIZE, BY EX VIVO, BY REGION, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL GENE THERAPY MARKET SIZE, BY EX VIVO, BY GROUP, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL GENE THERAPY MARKET SIZE, BY EX VIVO, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL GENE THERAPY MARKET SIZE, BY IN VIVO, BY REGION, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL GENE THERAPY MARKET SIZE, BY IN VIVO, BY GROUP, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL GENE THERAPY MARKET SIZE, BY IN VIVO, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL GENE THERAPY MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL GENE THERAPY MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL GENE THERAPY MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL GENE THERAPY MARKET SIZE, BY INTRAOCULAR, BY REGION, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL GENE THERAPY MARKET SIZE, BY INTRAOCULAR, BY GROUP, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL GENE THERAPY MARKET SIZE, BY INTRAOCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL GENE THERAPY MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL GENE THERAPY MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL GENE THERAPY MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL GENE THERAPY MARKET SIZE, BY ADULT PATIENTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL GENE THERAPY MARKET SIZE, BY ADULT PATIENTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL GENE THERAPY MARKET SIZE, BY ADULT PATIENTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL GENE THERAPY MARKET SIZE, BY PEDIATRIC PATIENTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL GENE THERAPY MARKET SIZE, BY PEDIATRIC PATIENTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL GENE THERAPY MARKET SIZE, BY PEDIATRIC PATIENTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL GENE THERAPY MARKET SIZE, BY CORONARY ARTERY DISEASE, BY REGION, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL GENE THERAPY MARKET SIZE, BY CORONARY ARTERY DISEASE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL GENE THERAPY MARKET SIZE, BY CORONARY ARTERY DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL GENE THERAPY MARKET SIZE, BY HEART FAILURE, BY REGION, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL GENE THERAPY MARKET SIZE, BY HEART FAILURE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL GENE THERAPY MARKET SIZE, BY HEART FAILURE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL GENE THERAPY MARKET SIZE, BY HEPATITIS B, BY REGION, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL GENE THERAPY MARKET SIZE, BY HEPATITIS B, BY GROUP, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL GENE THERAPY MARKET SIZE, BY HEPATITIS B, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL GENE THERAPY MARKET SIZE, BY HIV, BY REGION, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL GENE THERAPY MARKET SIZE, BY HIV, BY GROUP, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL GENE THERAPY MARKET SIZE, BY HIV, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 96. GLOBAL GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 97. GLOBAL GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 98. GLOBAL GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2032 (USD MILLION)
TABLE 99. GLOBAL GENE THERAPY MARKET SIZE, BY CYSTIC FIBROSIS, BY REGION, 2018-2032 (USD MILLION)
TABLE 100. GLOBAL GENE THERAPY MARKET SIZE, BY CYSTIC FIBROSIS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 101. GLOBAL GENE THERAPY MARKET SIZE, BY CYSTIC FIBROSIS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 102. GLOBAL GENE THERAPY MARKET SIZE, BY HEMOPHILIA, BY REGION, 2018-2032 (USD MILLION)
TABLE 103. GLOBAL GENE THERAPY MARKET SIZE, BY HEMOPHILIA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 104. GLOBAL GENE THERAPY MARKET SIZE, BY HEMOPHILIA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 105. GLOBAL GENE THERAPY MARKET SIZE, BY SICKLE CELL ANEMIA, BY REGION, 2018-2032 (USD MILLION)
TABLE 106. GLOBAL GENE THERAPY MARKET SIZE, BY SICKLE CELL ANEMIA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 107. GLOBAL GENE THERAPY MARKET SIZE, BY SICKLE CELL ANEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 108. GLOBAL GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 109. GLOBAL GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 110. GLOBAL GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 111. GLOBAL GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 112. GLOBAL GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 113. GLOBAL GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 114. GLOBAL GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 115. GLOBAL GENE THERAPY MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 116. GLOBAL GENE THERAPY MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 117. GLOBAL GENE THERAPY MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 118. GLOBAL GENE THERAPY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 119. GLOBAL GENE THERAPY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
TABLE 120. GLOBAL GENE THERAPY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 121. GLOBAL GENE THERAPY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 122. GLOBAL GENE THERAPY MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 123. GLOBAL GENE THERAPY MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 124. GLOBAL GENE THERAPY MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 125. GLOBAL GENE THERAPY MARKET SIZE, BY PHARMACEUTICAL & BIOTECH COMPANIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 126. GLOBAL GENE THERAPY MARKET SIZE, BY PHARMACEUTICAL & BIOTECH COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 127. GLOBAL GENE THERAPY MARKET SIZE, BY PHARMACEUTICAL & BIOTECH COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 128. GLOBAL GENE THERAPY MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
TABLE 129. GLOBAL GENE THERAPY MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 130. GLOBAL GENE THERAPY MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 131. GLOBAL GENE THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 132. AMERICAS GENE THERAPY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 133. AMERICAS GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
TABLE 134. AMERICAS GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2032 (USD MILLION)
TABLE 135. AMERICAS GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
TABLE 136. AMERICAS GENE THERAPY MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
TABLE 137. AMERICAS GENE THERAPY MARKET SIZE, BY SOMATIC CELL THERAPY, 2018-2032 (USD MILLION)
TABLE 138. AMERICAS GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2018-2032 (USD MILLION)
TABLE 139. AMERICAS GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 140. AMERICAS GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 141. AMERICAS GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 142. AMERICAS GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 143. AMERICAS GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
TABLE 144. AMERICAS GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 145. AMERICAS GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2032 (USD MILLION)
TABLE 146. AMERICAS GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 147. AMERICAS GENE THERAPY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 148. NORTH AMERICA GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 149. NORTH AMERICA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
TABLE 150. NORTH AMERICA GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2032 (USD MILLION)
TABLE 151. NORTH AMERICA GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
TABLE 152. NORTH AMERICA GENE THERAPY MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
TABLE 153. NORTH AMERICA GENE THERAPY MARKET SIZE, BY SOMATIC CELL THERAPY, 2018-2032 (USD MILLION)
TABLE 154. NORTH AMERICA GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2018-2032 (USD MILLION)
TABLE 155. NORTH AMERICA GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 156. NORTH AMERICA GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 157. NORTH AMERICA GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 158. NORTH AMERICA GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 159. NORTH AMERICA GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
TABLE 160. NORTH AMERICA GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 161. NORTH AMERICA GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2032 (USD MILLION)
TABLE 162. NORTH AMERICA GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 163. NORTH AMERICA GENE THERAPY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 164. LATIN AMERICA GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 165. LATIN AMERICA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
TABLE 166. LATIN AMERICA GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2032 (USD MILLION)
TABLE 167. LATIN AMERICA GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
TABLE 168. LATIN AMERICA GENE THERAPY MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
TABLE 169. LATIN AMERICA GENE THERAPY MARKET SIZE, BY SOMATIC CELL THERAPY, 2018-2032 (USD MILLION)
TABLE 170. LATIN AMERICA GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2018-2032 (USD MILLION)
TABLE 171. LATIN AMERICA GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 172. LATIN AMERICA GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 173. LATIN AMERICA GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 174. LATIN AMERICA GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 175. LATIN AMERICA GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
TABLE 176. LATIN AMERICA GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 177. LATIN AMERICA GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2032 (USD MILLION)
TABLE 178. LATIN AMERICA GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 179. LATIN AMERICA GENE THERAPY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 180. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 181. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
TABLE 182. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2032 (USD MILLION)
TABLE 183. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
TABLE 184. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
TABLE 185. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY SOMATIC CELL THERAPY, 2018-2032 (USD MILLION)
TABLE 186. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2018-2032 (USD MILLION)
TABLE 187. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 188. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 189. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 190. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 191. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
TABLE 192. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 193. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2032 (USD MILLION)
TABLE 194. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 195. EUROPE, MIDDLE EAST & AFRICA GENE THERAPY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 196. EUROPE GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 197. EUROPE GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
TABLE 198. EUROPE GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2032 (USD MILLION)
TABLE 199. EUROPE GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
TABLE 200. EUROPE GENE THERAPY MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
TABLE 201. EUROPE GENE THERAPY MARKET SIZE, BY SOMATIC CELL THERAPY, 2018-2032 (USD MILLION)
TABLE 202. EUROPE GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2018-2032 (USD MILLION)
TABLE 203. EUROPE GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 204. EUROPE GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 205. EUROPE GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 206. EUROPE GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 207. EUROPE GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
TABLE 208. EUROPE GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 209. EUROPE GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2032 (USD MILLION)
TABLE 210. EUROPE GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 211. EUROPE GENE THERAPY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 212. MIDDLE EAST GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 213. MIDDLE EAST GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
TABLE 214. MIDDLE EAST GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2032 (USD MILLION)
TABLE 215. MIDDLE EAST GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
TABLE 216. MIDDLE EAST GENE THERAPY MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
TABLE 217. MIDDLE EAST GENE THERAPY MARKET SIZE, BY SOMATIC CELL THERAPY, 2018-2032 (USD MILLION)
TABLE 218. MIDDLE EAST GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2018-2032 (USD MILLION)
TABLE 219. MIDDLE EAST GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 220. MIDDLE EAST GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 221. MIDDLE EAST GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 222. MIDDLE EAST GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 223. MIDDLE EAST GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
TABLE 224. MIDDLE EAST GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 225. MIDDLE EAST GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2032 (USD MILLION)
TABLE 226. MIDDLE EAST GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 227. MIDDLE EAST GENE THERAPY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 228. AFRICA GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 229. AFRICA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
TABLE 230. AFRICA GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2032 (USD MILLION)
TABLE 231. AFRICA GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
TABLE 232. AFRICA GENE THERAPY MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
TABLE 233. AFRICA GENE THERAPY MARKET SIZE, BY SOMATIC CELL THERAPY, 2018-2032 (USD MILLION)
TABLE 234. AFRICA GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2018-2032 (USD MILLION)
TABLE 235. AFRICA GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 236. AFRICA GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 237. AFRICA GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 238. AFRICA GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 239. AFRICA GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
TABLE 240. AFRICA GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 241. AFRICA GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2032 (USD MILLION)
TABLE 242. AFRICA GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 243. AFRICA GENE THERAPY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 244. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 245. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
TABLE 246. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2032 (USD MILLION)
TABLE 247. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
TABLE 248. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
TABLE 249. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY SOMATIC CELL THERAPY, 2018-2032 (USD MILLION)
TABLE 250. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2018-2032 (USD MILLION)
TABLE 251. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 252. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 253. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 254. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 255. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
TABLE 256. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 257. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2032 (USD MILLION)
TABLE 258. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 259. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 260. GLOBAL GENE THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 261. ASEAN GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 262. ASEAN GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
TABLE 263. ASEAN GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2032 (USD MILLION)
TABLE 264. ASEAN GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
TABLE 265. ASEAN GENE THERAPY MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
TABLE 266. ASEAN GENE THERAPY MARKET SIZE, BY SOMATIC CELL THERAPY, 2018-2032 (USD MILLION)
TABLE 267. ASEAN GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2018-2032 (USD MILLION)
TABLE 268. ASEAN GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 269. ASEAN GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 270. ASEAN GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 271. ASEAN GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 272. ASEAN GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
TABLE 273. ASEAN GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 274. ASEAN GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2032 (USD MILLION)
TABLE 275. ASEAN GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 276. ASEAN GENE THERAPY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 277. GCC GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 278. GCC GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
TABLE 279. GCC GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2032 (USD MILLION)
TABLE 280. GCC GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
TABLE 281. GCC GENE THERAPY MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
TABLE 282. GCC GENE THERAPY MARKET SIZE, BY SOMATIC CELL THERAPY, 2018-2032 (USD MILLION)
TABLE 283. GCC GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2018-2032 (USD MILLION)
TABLE 284. GCC GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 285. GCC GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 286. GCC GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 287. GCC GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 288. GCC GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
TABLE 289. GCC GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 290. GCC GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2032 (USD MILLION)
TABLE 291. GCC GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 292. GCC GENE THERAPY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 293. EUROPEAN UNION GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 294. EUROPEAN UNION GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
TABLE 295. EUROPEAN UNION GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2032 (USD MILLION)
TABLE 296. EUROPEAN UNION GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
TABLE 297. EUROPEAN UNION GENE THERAPY MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
TABLE 298. EUROPEAN UNION GENE THERAPY MARKET SIZE, BY SOMATIC CELL THERAPY, 2018-2032 (USD MILLION)
TABLE 299. EUROPEAN UNION GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2018-2032 (USD MILLION)
TABLE 300. EUROPEAN UNION GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 301. EUROPEAN UNION GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 302. EUROPEAN UNION GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 303. EUROPEAN UNION GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 304. EUROPEAN UNION GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
TABLE 305. EUROPEAN UNION GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 306. EUROPEAN UNION GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2032 (USD MILLION)
TABLE 307. EUROPEAN UNION GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 308. EUROPEAN UNION GENE THERAPY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 309. BRICS GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 310. BRICS GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
TABLE 311. BRICS GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2032 (USD MILLION)
TABLE 312. BRICS GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
TABLE 313. BRICS GENE THERAPY MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
TABLE 314. BRICS GENE THERAPY MARKET SIZE, BY SOMATIC CELL THERAPY, 2018-2032 (USD MILLION)
TABLE 315. BRICS GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2018-2032 (USD MILLION)
TABLE 316. BRICS GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 317. BRICS GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 318. BRICS GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 319. BRICS GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 320. BRICS GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
TABLE 321. BRICS GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 322. BRICS GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2032 (USD MILLION)
TABLE 323. BRICS GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 324. BRICS GENE THERAPY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 325. G7 GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 326. G7 GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
TABLE 327. G7 GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2032 (USD MILLION)
TABLE 328. G7 GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
TABLE 329. G7 GENE THERAPY MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
TABLE 330. G7 GENE THERAPY MARKET SIZE, BY SOMATIC CELL THERAPY, 2018-2032 (USD MILLION)
TABLE 331. G7 GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2018-2032 (USD MILLION)
TABLE 332. G7 GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
TABLE 333. G7 GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 334. G7 GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 335. G7 GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 336. G7 GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
TABLE 337. G7 GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
TABLE 338. G7 GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2032 (USD MILLION)
TABLE 339. G7 GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
TABLE 340. G7 GENE THERAPY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 341. NATO GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 342. NATO GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
TABLE 343. NATO GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2032 (USD MILLION)
TABLE 344. NATO GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
TABLE 345. NATO GENE THERAPY MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
TABLE 346. NATO GENE THERAPY MARKET SIZE, BY SOMA

Companies Mentioned

The key companies profiled in this Gene Therapy market report include:
  • Abeona Therapeutics Inc.
  • Adaptimmune Therapeutics PLC
  • Adverum Biotechnologies, Inc.
  • AGC Biologics
  • Alnylam Pharmaceuticals, Inc.
  • American Gene Technologies Inc.
  • Amgen Inc.
  • AnGes, Inc.
  • Astellas Pharma Inc.
  • Biogen Inc.
  • bluebird bio, Inc.
  • Cellectis S.A.
  • CRISPR Therapeutics AG
  • Danaher Corporation
  • Editas Medicine, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • Intellia Therapeutics
  • Ionis Pharmaceuticals, Inc.
  • Johnson & Johnson
  • Merck KGaA
  • Mustang Bio, Inc.
  • Novartis AG
  • Orchard Therapeutics PLC
  • Poseida Therapeutics, Inc.
  • Sangamo Therapeutics, Inc.
  • Sarepta Therapeutics, Inc.
  • Sibiono GeneTech Co. Ltd.
  • Syncona Limited
  • ViGeneron GmbH
  • Voyager Therapeutics Inc.

Table Information

Report AttributeDetails
No. of Pages199
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 16.35 Billion
Forecasted Market Value ( USD ) by 2032 $ 75.92 Billion
Compound Annual Growth Rate28.8%
Regions CoveredGlobal
No. of Companies Mentioned32

Related Topics

Related Reports

Cell & Gene Therapy Manufacturing Services Market - Global Forecast 2025-2032 - Product Image

Cell & Gene Therapy Manufacturing Services Market - Global Forecast 2025-2032

  • Report
  • 193 Pages
  • Global
From
Gene Therapy Market - Global Industry Size, Share, Trends, Opportunity and Forecast, 2020-2030F - Product Image

Gene Therapy Market - Global Industry Size, Share, Trends, Opportunity and Forecast, 2020-2030F

  • Report
  • 187 Pages
  • Global
From
Cell & Gene Therapy Clinical Trials Market - Global Forecast 2025-2032 - Product Image

Cell & Gene Therapy Clinical Trials Market - Global Forecast 2025-2032

  • Report
  • 186 Pages
  • Global
From
Adeno-Associated Virus (AVV) Vectors in Gene Therapy Market Report 2025 - Product Image

Adeno-Associated Virus (AVV) Vectors in Gene Therapy Market Report 2025

  • Report
  • 250 Pages
  • Global
From
Gene Therapy for Inherited Genetic Disorders Market Report 2025 - Product Image

Gene Therapy for Inherited Genetic Disorders Market Report 2025

  • Report
  • 250 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.